MXPA01008137A - Secuencias antisensa antitumorales dirigidas en contra de los componentes r1 y r2 de la reductasa de ribonucleotido. - Google Patents
Secuencias antisensa antitumorales dirigidas en contra de los componentes r1 y r2 de la reductasa de ribonucleotido.Info
- Publication number
- MXPA01008137A MXPA01008137A MXPA01008137A MXPA01008137A MXPA01008137A MX PA01008137 A MXPA01008137 A MX PA01008137A MX PA01008137 A MXPA01008137 A MX PA01008137A MX PA01008137 A MXPA01008137 A MX PA01008137A MX PA01008137 A MXPA01008137 A MX PA01008137A
- Authority
- MX
- Mexico
- Prior art keywords
- ribonucleotide reductase
- components
- directed against
- antisense sequences
- sequences directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El presente invento proporciona un oligonucleotido de la antisensa menos que aproximadamente 50 nucleotidos comprendiendo la secuencia de AS-I-618-20 [Numero de identificacion de la secuencia: 176]. Esta secuencia puede ademas comprender la formacion reducida de dimer, asi como interacciones autocomplementarias reducidas. Tambien se proporciona una composicion farmaceutica para inhibir el crecimiento de la celula del tumor en un mamifero comprendiendo una cantidad eficaz he un oligonucleotido de la antisensa menos que aproximadamente 50 oligonucleotidos comprendiendo la secuencia de AS-I-618-20 [Numero de identificacion de la secuencia: 176]. En uno de sus aspectos del metodo, este invento proporciona un metodo para inhibir la tumorigenocidad de celulas neoplasticas con una cantidad eficaz de un oligonucleotido de antisensa que comprende la secuencia de AS-I-618-20 [Numero de identificacion de la secuencia: 176]. Otro aspecto es un metodo para inhibir la tumorigenocidad de las celulas neoplasticas resistentes a farmacos quimioterapeuticos en mamiferos, cuyo metodo comprende el identificar pacientes que tienen tumores que son resistentes al farmaco quimioterapeutico; y contactando el tumor con el farmaco quimioterapeutico al que el tumor es resistente y un oligonucleotido de la antisensa que comprenda la secuencia de AS-I-618-20 [Numero de identificacion de la secuencia: 176] donde la cantidad de farmaco quimioterapeutico y el oligonucleotido de la antisensa es suficiente para inhibir el crecimiento de la celula del tumor. La cantidad de oligonucleotido de la antisensa por si solo puede ser insuficiente para inhibir dicho crecimiento. Otro aspecto es un metodo para aumentar la sensibilidad de las celulas neoplasticas para los farmacos quimioterapeuticos en un mamifero al contactar el tumor con un oligonucleotido de la antisensa que contenga la secuencia AS-I-618-20 [Numero de identificacion de la secuencia: 176]. Otro aspecto es un metodo para inhibir la metastasis de celulas del tumor en un mamifero, cuyo metodo comprenda la administracion a dicho mamifero de una cantidad suficiente para inhibir el crecimiento de la celula del tumor de un oligonucleotido de la antisensa que comprenda la secuencia de AS-I-618-20 [Numero de identificacion de la secuencia: 176]. Otro aspecto es un ADN aislado con una secuencia que comprenda una region de iniciacion transcripcional y una secuencia que codifique un oligonucleotido de la antisensa menos que aproximadamente 50 nucleotidos que contengan la secuencia de AS-I-618-20 [Numero de identificacion de la secuencia: 176].
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/249,730 US6121000A (en) | 1999-02-11 | 1999-02-11 | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
| PCT/CA2000/000120 WO2000047733A1 (en) | 1999-02-11 | 2000-02-09 | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA01008137A true MXPA01008137A (es) | 2004-08-12 |
Family
ID=22944744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA01008137A MXPA01008137A (es) | 1999-02-11 | 2000-02-09 | Secuencias antisensa antitumorales dirigidas en contra de los componentes r1 y r2 de la reductasa de ribonucleotido. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6121000A (es) |
| EP (1) | EP1153128B8 (es) |
| JP (1) | JP4424857B2 (es) |
| KR (1) | KR20020013501A (es) |
| CN (1) | CN1345373A (es) |
| AR (1) | AR022583A1 (es) |
| AT (1) | ATE309346T1 (es) |
| AU (1) | AU780455B2 (es) |
| BR (1) | BR0008788A (es) |
| CA (1) | CA2366487A1 (es) |
| DE (1) | DE60023845T2 (es) |
| ES (1) | ES2259602T3 (es) |
| IL (1) | IL144727A0 (es) |
| MX (1) | MXPA01008137A (es) |
| NZ (1) | NZ514090A (es) |
| RU (1) | RU2001124840A (es) |
| WO (1) | WO2000047733A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593305B1 (en) * | 1996-08-02 | 2003-07-15 | Genesense Technologies Inc. | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
| ES2397060T3 (es) * | 2002-04-18 | 2013-03-04 | Opko Pharmaceuticals, Llc | Medios y métodos para la modulación específica de genes diana en el ojo |
| US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| WO2004070033A1 (en) | 2003-02-10 | 2004-08-19 | Genesense Technologies Inc. | Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer |
| WO2004094606A2 (en) * | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2 |
| CN1302936C (zh) * | 2003-05-02 | 2007-03-07 | 精工爱普生株式会社 | 打印机 |
| US20070274947A1 (en) * | 2003-05-21 | 2007-11-29 | Young Aiping H | Antisense Oligonucleotides Directed to Ribonucleotide Reductase R1 and Uses Thereof in the Treatment of Cancer |
| WO2004106518A1 (en) * | 2003-05-31 | 2004-12-09 | Genesense Technologies Inc. | Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer |
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| US20080311126A1 (en) * | 2004-01-12 | 2008-12-18 | Genesense Technologies, Inc | Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer |
| US8029815B2 (en) * | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
| EP1786905B1 (en) * | 2004-08-18 | 2011-08-03 | Lorus Therapeutics Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
| WO2007133758A1 (en) * | 2006-05-15 | 2007-11-22 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
| US20080152654A1 (en) * | 2006-06-12 | 2008-06-26 | Exegenics, Inc., D/B/A Opko Health, Inc. | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
| US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
| US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
| US9526707B2 (en) * | 2007-08-13 | 2016-12-27 | Howard L. Elford | Methods for treating or preventing neuroinflammation or autoimmune diseases |
| US20100204305A1 (en) * | 2007-12-11 | 2010-08-12 | Lorus Therapeutics Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
| US8470792B2 (en) | 2008-12-04 | 2013-06-25 | Opko Pharmaceuticals, Llc. | Compositions and methods for selective inhibition of VEGF |
| DE102019000490A1 (de) * | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
| US5766855A (en) * | 1991-05-24 | 1998-06-16 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity and sequence specificity |
| US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5681747A (en) * | 1992-03-16 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof |
| EP0690869A1 (en) * | 1993-03-23 | 1996-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Cellular regulation with riboregulators |
| ES2256893T3 (es) * | 1996-08-02 | 2006-07-16 | Genesense Technologies Inc. | Secuencias antisentido antitumorales dirigidas contra componentes r1 y r2 de la reductasa ribonucleica. |
-
1999
- 1999-02-11 US US09/249,730 patent/US6121000A/en not_active Expired - Fee Related
-
2000
- 2000-02-09 CN CN00805667A patent/CN1345373A/zh active Pending
- 2000-02-09 DE DE60023845T patent/DE60023845T2/de not_active Expired - Lifetime
- 2000-02-09 IL IL14472700A patent/IL144727A0/xx unknown
- 2000-02-09 MX MXPA01008137A patent/MXPA01008137A/es not_active Application Discontinuation
- 2000-02-09 KR KR1020017010204A patent/KR20020013501A/ko not_active Application Discontinuation
- 2000-02-09 CA CA002366487A patent/CA2366487A1/en not_active Abandoned
- 2000-02-09 JP JP2000598631A patent/JP4424857B2/ja not_active Expired - Fee Related
- 2000-02-09 WO PCT/CA2000/000120 patent/WO2000047733A1/en active IP Right Grant
- 2000-02-09 ES ES00903456T patent/ES2259602T3/es not_active Expired - Lifetime
- 2000-02-09 RU RU2001124840/15A patent/RU2001124840A/ru unknown
- 2000-02-09 EP EP00903456A patent/EP1153128B8/en not_active Expired - Lifetime
- 2000-02-09 AT AT00903456T patent/ATE309346T1/de not_active IP Right Cessation
- 2000-02-09 AU AU25292/00A patent/AU780455B2/en not_active Ceased
- 2000-02-09 NZ NZ514090A patent/NZ514090A/en not_active IP Right Cessation
- 2000-02-09 BR BR0008788-2A patent/BR0008788A/pt not_active Application Discontinuation
- 2000-02-11 AR ARP000100613A patent/AR022583A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000047733A9 (en) | 2001-03-15 |
| EP1153128B1 (en) | 2005-11-09 |
| AU780455B2 (en) | 2005-03-24 |
| ES2259602T3 (es) | 2006-10-16 |
| WO2000047733A1 (en) | 2000-08-17 |
| RU2001124840A (ru) | 2004-03-27 |
| NZ514090A (en) | 2005-01-28 |
| EP1153128A1 (en) | 2001-11-14 |
| IL144727A0 (en) | 2002-06-30 |
| KR20020013501A (ko) | 2002-02-20 |
| CA2366487A1 (en) | 2000-08-17 |
| AR022583A1 (es) | 2002-09-04 |
| DE60023845D1 (de) | 2005-12-15 |
| US6121000A (en) | 2000-09-19 |
| AU2529200A (en) | 2000-08-29 |
| BR0008788A (pt) | 2001-11-06 |
| ATE309346T1 (de) | 2005-11-15 |
| JP4424857B2 (ja) | 2010-03-03 |
| EP1153128B8 (en) | 2006-01-18 |
| CN1345373A (zh) | 2002-04-17 |
| DE60023845T2 (de) | 2006-08-10 |
| JP2003500006A (ja) | 2003-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA01008137A (es) | Secuencias antisensa antitumorales dirigidas en contra de los componentes r1 y r2 de la reductasa de ribonucleotido. | |
| CA2262776A1 (en) | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase | |
| WO1998000532A3 (en) | Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth | |
| AU7585598A (en) | Raf kinase inhibitors | |
| EP1117672A4 (en) | ANTISENSE MODULATION OF THE SURVIVIN EXPRESSION | |
| EP1131465A4 (en) | ANTISENSE MODULATION OF THE INTERLEUKIN-15 EXPRESSION | |
| PL343083A1 (en) | Inhibition of raf kinase using substituted heterocyclic ureas | |
| EP1190099A4 (en) | ANTISENSE MODULATION OF THE P13K P85 EXPRESSION | |
| EP1507005A3 (en) | Antisense modulation of BCL-X expression | |
| GR20010300010T1 (en) | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas | |
| GB9927444D0 (en) | Inhibiting gene expression | |
| HK1028350A1 (en) | Leptin as an inhibitor of tumor cell proliferation. | |
| MY138257A (en) | Compositions and methods for enhancing delivery of therapeutic agents to cells | |
| WO2002030465A3 (en) | Compositions that inhibit proliferation of cancer cells | |
| EP1135402A4 (en) | ANTISENSE MODULATION OF THE EGR-1 EXPRESSION | |
| AU2904300A (en) | Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity | |
| AU2290000A (en) | Phenanthridine-n-oxides with pde-iv inhibiting activity | |
| EP1224202A4 (en) | ANTISENSE MODULATION OF INTEGRIN MEDIUM KINASE EXPRESSION | |
| HUP0104046A2 (hu) | Adenovírus-közvetített génterápia | |
| GB2378948B (en) | Novel compounds for modulating cell proliferation | |
| AU2289400A (en) | 6-arylphenanthridines with pde-iv inhibiting activity | |
| WO2003105755A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION | |
| EP1165145A4 (en) | ANTISENSE REGULATION OF MDMX EXPRESSION | |
| IL137177A0 (en) | Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth | |
| EP1218395A4 (en) | ANTISENSE MODULATION OF X-CONNECTED INHIBITORS OF APOPTOSIS EXPRESSION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights | ||
| FA | Abandonment or withdrawal |